Hamilton BioVentures

Hamilton BioVentures is a California-based venture capital firm established in 2000, managing $100 million in assets. The firm focuses on investing in early-stage biotechnology companies in the United States, particularly those developing innovative treatments in biopharmaceuticals and medical devices aimed at addressing significant human diseases and medical conditions. Hamilton BioVentures primarily provides direct equity investments to talented entrepreneurs on the West Coast who are working to bring new life science technologies to market.

Kerry Dance

Managing Director

8 past transactions

Splash Pharmaceuticals

Series D in 2018
Splash Pharmaceuticals, Inc. is a clinical-stage oncology company based in San Diego, California, focused on developing innovative cancer therapies. Founded in 2001, the company is advancing its lead product, SPL-108, which targets CD44 to elicit durable responses in cancer patients. Splash Pharmaceuticals has created a pipeline of novel agents that exhibit anti-angiogenic and anti-metastatic properties, as well as synergistic cytotoxic effects when combined with other chemotherapy agents. In addition to its cancer-focused initiatives, the company is also exploring therapies for arthritis. Splash is actively seeking partnerships with pharmaceutical companies to expedite the development of its clinical programs.

PhotoThera

Series D in 2009
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Ceregene

Series C in 2007
Ceregene is a private biotechnology company based in San Diego, specializing in treatments for major neurodegenerative disorders through the delivery of nervous system growth factors. The company's clinical programs include CERE-110, an AAV2-based vector designed to express nerve growth factor, which is set to enter Phase 2 trials for Alzheimer's disease. Additionally, Ceregene is advancing CERE-120, which has completed Phase 2 trials for Parkinson's disease and is currently under evaluation for further development. The company is also developing CERE-135 and CERE-140, both of which are in preclinical stages, targeting amyotrophic lateral sclerosis (ALS) and various ocular diseases, respectively.

Transcept Pharmaceuticals

Series D in 2007
Transcept Pharmaceuticals, Inc. is engaged in the development of proprietary products aimed at addressing therapeutic needs in neuroscience. The company utilizes a unique delivery system that enhances drug penetration and accelerates their onset of action. Transcept is focused on creating rapid-acting formulations of several established pharmaceuticals, seeking to improve patient outcomes in various neurological conditions. The company has attracted investment from notable firms, including Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates, supporting its ongoing research and development efforts.

Kemia

Series C in 2006
Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

PhotoThera

Series C in 2006
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

PhotoThera

Series B in 2005
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Troika Networks

Series B in 2005
Troika Networks, Inc. specializes in providing integrated solutions for storage network data protection and management. Founded in 1998 and headquartered in Westlake Village, California, the company offers flexible SAN-based storage management solutions designed to enhance disaster recovery, backup, and volume management functionalities. Its offerings include application hosting platforms and embedded technologies that enable original equipment manufacturers and resellers to implement cost-effective data protection strategies worldwide. Utilizing its Accelera Network Storage Services Platforms and ReadyPath Technology, Troika Networks aims to significantly improve the data management capabilities of enterprise customers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.